Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Goodwill (2016 - 2019)

Historic Goodwill for Ironwood Pharmaceuticals (IRWD) over the last 4 years, with Q4 2019 value amounting to $785000.0.

  • Ironwood Pharmaceuticals' Goodwill changed 0.0% to $785000.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $785000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $785000.0 for FY2019, which is 0.0% changed from last year.
  • According to the latest figures from Q4 2019, Ironwood Pharmaceuticals' Goodwill is $785000.0, which was down 0.0% from $785000.0 recorded in Q3 2019.
  • In the past 5 years, Ironwood Pharmaceuticals' Goodwill registered a high of $785000.0 during Q4 2016, and its lowest value of $649000.0 during Q2 2016.
  • Over the past 4 years, Ironwood Pharmaceuticals' median Goodwill value was $785000.0 (recorded in 2016), while the average stood at $766866.7.
  • Over the last 5 years, Ironwood Pharmaceuticals' Goodwill had its largest YoY gain of 2095.53% in 2017, and its largest YoY loss of 0.0% in 2017.
  • Ironwood Pharmaceuticals' Goodwill (Quarter) stood at $785000.0 in 2016, then changed by 0.0% to $785000.0 in 2017, then changed by 0.0% to $785000.0 in 2018, then changed by 0.0% to $785000.0 in 2019.
  • Its last three reported values are $785000.0 in Q4 2019, $785000.0 for Q3 2019, and $785000.0 during Q2 2019.